Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

BioXcel Therapeutics (BTAI) Accumulated Depreciation & Amortization (2022 - 2025)

Historic Accumulated Depreciation & Amortization for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $1.7 million.

  • BioXcel Therapeutics' Accumulated Depreciation & Amortization rose 2126.32% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 2126.32%. This contributed to the annual value of $1.5 million for FY2024, which is 2590.11% up from last year.
  • As of Q3 2025, BioXcel Therapeutics' Accumulated Depreciation & Amortization stood at $1.7 million, which was up 2126.32% from $1.7 million recorded in Q2 2025.
  • Over the past 5 years, BioXcel Therapeutics' Accumulated Depreciation & Amortization peaked at $1.7 million during Q3 2025, and registered a low of $679000.0 during Q1 2022.
  • In the last 4 years, BioXcel Therapeutics' Accumulated Depreciation & Amortization had a median value of $1.2 million in 2023 and averaged $1.2 million.
  • In the last 5 years, BioXcel Therapeutics' Accumulated Depreciation & Amortization soared by 4212.08% in 2023 and then surged by 2126.32% in 2025.
  • BioXcel Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $885000.0 in 2022, then surged by 34.8% to $1.2 million in 2023, then grew by 25.9% to $1.5 million in 2024, then grew by 15.05% to $1.7 million in 2025.
  • Its Accumulated Depreciation & Amortization was $1.7 million in Q3 2025, compared to $1.7 million in Q2 2025 and $1.6 million in Q1 2025.